{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:12Z","timestamp":1792088172801,"version":"4.4.0"},"reference-count":144,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":9822,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1985,3,4]]},"abstract":"<jats:p>Glyburide, a second\u2010generation hypoglycemic sulfonylurea, is 200 times as potent as tolbutamide. This increase is due to greater intrinsic hypoglycemic potency of the molecule rather than to a prolonged biologic half\u2010life. Glyburide is inactivated by the liver to 4\u2010trans\u2010hydroxyglyburide and 3\u2010cis\u2010hydroxyglyburide; 50% of these compounds is excreted in the urine and 50% in the bile. Although the serum concentration of glyburide can be measured by radioimmunoassay and high\u2010performance liquid chromatography, the importance of its serum concentration in the reduction of hyperglycemia is not yet established. Glyburide has a therapeutic effectiveness comparable to that of the first\u2010generation sulfonylurea chlorpropamide; however, it has a lower frequency of adverse effects. To date it has a low frequency of clinically significant interactions with other drugs. Glyburide should not be prescribed for patients with liver disease or significant renal disease. Because glyburide is a potent hypoglycemic agent, it should be prescribed in small initial doses, particularly for elderly patients with diabetes. At the present time there is no definite evidence that it modifies the increased risk of cardiovascular disease of diabetic patients. Although glyburide is a potent stimulator of pancreatic insulin secretion after short\u2010term administration, an additional mechanism of action during long\u2010term administration is to decrease the resistance of muscle and liver to the action of insulin. It is a useful medication for patients with type II diabetes whose hyperglycemia is not adequately reduced by dietary management and exercise. It can be used as the initial drug in these patients or as the replacement drug for those with primary or secondary failure during therapy with first\u2010generation sulfonylureas.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1985.tb03404.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T17:36:41Z","timestamp":1450287401000},"page":"43-62","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Glyburide: A Second\u2010generation Sulfonylurea Hypoglycemic Agent"],"prefix":"10.1002","volume":"5","author":[{"given":"Jerome M.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"issue":"1","key":"e_1_2_1_2_2","first-page":"20","article-title":"The discovery of hypoglycemic sulfonamides and particularly of their action mechanism","volume":"6","author":"Loubatieres A.","year":"1969","journal-title":"Acta Diabetol Lat"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90773-7"},{"key":"e_1_2_1_4_2","first-page":"1","article-title":"HB419 \u2014 a new oral antidiabetic drug","volume":"1","author":"Levine R","year":"1969","journal-title":"Horm Metab Res"},{"key":"e_1_2_1_5_2","first-page":"1","article-title":"Glibenclamide","volume":"46","author":"Lewis AAG","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_6_2","first-page":"12","volume-title":"Micronase: pharmacological and clinical evaluation. International congress series 382","author":"Rifkin H","year":"1975"},{"key":"e_1_2_1_7_2","first-page":"31","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Kaiser DG","year":"1975"},{"key":"e_1_2_1_8_2","first-page":"1400","article-title":"Metabolism von HB419 Am Tier","volume":"19","author":"Heptner W","year":"1969","journal-title":"Arzneim Forsch"},{"key":"e_1_2_1_9_2","first-page":"51","article-title":"Investigations on absorption, excretion and metabolism in man after administration of 14C\u2010labelled HB419","volume":"1","author":"Christ OE","year":"1969","journal-title":"Horm Metab Res"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01468104"},{"key":"e_1_2_1_11_2","first-page":"20","volume-title":"Micronase: pharmacological and clinical evaluation. International Congress series 382","author":"Ko H","year":"1975"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00032717608059126"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561783"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1980.tb01199.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/diab.28.3.221","article-title":"Radioimmunoassay of glibenclamide","volume":"28","author":"Kawashima K","year":"1979","journal-title":"Diabetes"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257728"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac00245a008"},{"key":"e_1_2_1_18_2","first-page":"1428","article-title":"Resorption, Ausscheidung und Metabolismus nach intravenoser und oraler Gabe von HB419 14C an Menschen","volume":"19","author":"Rupp W","year":"1969","journal-title":"Arzneim Forsch"},{"key":"e_1_2_1_19_2","first-page":"471","article-title":"Untersuchungen zur Bioavailability von Glibenclamid","volume":"22","author":"Rupp W","year":"1972","journal-title":"Arzneim Forsch"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01228296"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00563012"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542327"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1018613"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00616416"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.14.6.362"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1018746"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561585"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6106.142"},{"key":"e_1_2_1_29_2","first-page":"119","article-title":"Chlorpropamide and glibenclamide serum concentration in hospitalized patients","volume":"14","author":"Hupponen R","year":"1982","journal-title":"Ann Clin Res"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(72)90352-8"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00568895"},{"key":"e_1_2_1_32_2","first-page":"146","article-title":"Half\u2010life of intravenous tolbutamide in the serum of patients in medical wards","volume":"6","author":"Sotaniemi EA","year":"1974","journal-title":"Ann Clin Res"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.28.1.41"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972135part1710"},{"key":"e_1_2_1_35_2","first-page":"275","volume-title":"Applied pharmacokinetics \u2014 principles of therapeutics drug monitoring","author":"Tozer TN","year":"1982"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.5.5.497"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.28.12.1039"},{"key":"e_1_2_1_38_2","first-page":"84","article-title":"Second\u2010generation sulfonylureas: what are they and what is their value?","volume":"2","author":"Lebovitz HE.","year":"1984","journal-title":"Clinical Diabetes"},{"key":"e_1_2_1_39_2","first-page":"64","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Feldman JM","year":"1975"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91258-2"},{"key":"e_1_2_1_41_2","first-page":"140","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Londono JH","year":"1975"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253812"},{"key":"e_1_2_1_43_2","first-page":"66","article-title":"A comparison of glibenclamide with chlorpropamide in newly diagnosed maturity\u2010onset diabetes","volume":"46","author":"Gurling KJ.","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_44_2","first-page":"57","article-title":"Comparison of short\u2010term effects of glibenclamide and chlorpropamide in newly diagnosed diabetes","volume":"46","author":"FitzGerald MG","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.4.2.293"},{"key":"e_1_2_1_46_2","first-page":"185","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Graber AL.","year":"1975"},{"key":"e_1_2_1_47_2","first-page":"404","article-title":"UK prospective study of therapies of maturity\u2010onset diabetes. 1. Effect of diet, sulphonylureas, insulin or biguanide therapy on fasting plasma glucose and body weight over one year","volume":"24","author":"Multi\u2010center Study.","year":"1983","journal-title":"Diabetologia"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91141-1"},{"key":"e_1_2_1_49_2","first-page":"53","article-title":"Clinical studies on glibenclamide (HB419)","volume":"1","author":"Retiene K","year":"1969","journal-title":"Horm Metab Res"},{"key":"e_1_2_1_50_2","first-page":"60","article-title":"Clinical experience with glibenclamide in 300 diabetics","volume":"46","author":"Beyers J","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_51_2","first-page":"60","article-title":"Experience with glibenclamide in three diabetic clinics","volume":"46","author":"Brearly BF","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_52_2","first-page":"63","article-title":"Glibenclamide for secondary failure of other sulphonylureas","volume":"46","author":"Stowers JM.","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)91844-1"},{"issue":"2","key":"e_1_2_1_54_2","first-page":"74","article-title":"Five years experience with tolbutamide","volume":"11","author":"Camerini\u2010Davalos RO","year":"1962","journal-title":"Diabetes"},{"key":"e_1_2_1_55_2","first-page":"254","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Gundersen K","year":"1975"},{"key":"e_1_2_1_56_2","first-page":"5","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Webster HD","year":"1975"},{"key":"e_1_2_1_57_2","first-page":"69","article-title":"Analysis of long\u2010term experience with tolbutamide (Orinase) in the management of diabetes","volume":"1","author":"O'Donovan CJ.","year":"1959","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(64)90123-4"},{"key":"e_1_2_1_59_2","first-page":"82","volume-title":"Diabetes","author":"Macleod AG.","year":"1969"},{"key":"e_1_2_1_60_2","first-page":"570","article-title":"Clinical experience with chlorpropamide in management of diabetes mellitus","volume":"9","author":"Shlevin EL","year":"1960","journal-title":"Metabolism"},{"key":"e_1_2_1_61_2","first-page":"91","article-title":"Long\u2010term experience with chlorpropamide in diabetes mellitus","volume":"11","author":"Hadden DR","year":"1962","journal-title":"Diabetes"},{"issue":"2","key":"e_1_2_1_62_2","first-page":"39","article-title":"The clinical evaluation of an oral antidiabetic drug","volume":"1","author":"Muller R.","year":"1971","journal-title":"Aust NZ J Med"},{"key":"e_1_2_1_63_2","first-page":"296","volume-title":"Worldwide clinical experience with glipizide: an overview. In Glipizide: A World Wide Review","author":"Ostman J.","year":"1984"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.23.9.739"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1103938"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197101142840202"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.6.5.468"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-78-4-541"},{"key":"e_1_2_1_69_2","first-page":"105","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Moses AM.","year":"1975"},{"key":"e_1_2_1_70_2","first-page":"173","article-title":"Effects of glipizide on water and electrolyte handling in water\u2010loaded humans","volume":"4","author":"Preuss HG","year":"1981","journal-title":"Renal Physiol"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1159\/000178651"},{"key":"e_1_2_1_72_2","first-page":"40","article-title":"Alcohol sensitivity in diabetics receiving chlorpropamide","volume":"11","author":"Fitzgerald MG","year":"1962","journal-title":"Diabetes"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.17.11.679"},{"key":"e_1_2_1_74_2","first-page":"95","article-title":"Clinical experience with glibenclamide","volume":"46","author":"Galbraith HJB.","year":"1970","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5773.533"},{"key":"e_1_2_1_76_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0031-6997(25)07146-7","article-title":"Pharmacological implications of microsomal enzyme induction","volume":"19","author":"Conney AH.","year":"1967","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-196907000-00005"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1971.tb00552.x"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197713010-00003"},{"key":"e_1_2_1_80_2","first-page":"37","article-title":"Sulfonylureas: mechanisms of drug interactions; strategies to reduce them","volume":"24","author":"Feldman JM.","year":"1984","journal-title":"Consultant"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(76)90365-8"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.21.9.955"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257338"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.12.5.414"},{"key":"e_1_2_1_85_2","first-page":"120","article-title":"Behavior of chlorpropamide in renal insufficiency and under the effect of associated drug therapy","volume":"6","author":"Petitpierre B","year":"1972","journal-title":"Int J Clin Pharmacol"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196710262771701"},{"key":"e_1_2_1_87_2","first-page":"1782","article-title":"Les metabolites des sulfonylurees hypoglycemiantes dans l'insuffisance renale","volume":"108","author":"Loutan L","year":"1978","journal-title":"Schwiez Med Wochenschr"},{"key":"e_1_2_1_88_2","unstructured":"K\u00fchnleHF BehrleM HrstkaV SchmidtFH.Investigations on the pharmacokinetics of glibenclamide in patients with normal and markedly reduced renal function (abstract). Program of the eleventh congress of the international diabetes federation. Nairobi Kenya.Nov 1017 1982."},{"issue":"1","key":"e_1_2_1_89_2","first-page":"409","article-title":"Pharmacokinetic disposition of 14C\u2010glyburide in patients with varying renal function","volume":"33","author":"Pearson JG","year":"1984","journal-title":"Diabetes"},{"issue":"2","key":"e_1_2_1_90_2","first-page":"785","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult\u2010onset diabetes. II. Mortality results","volume":"19","author":"University Group Diabetes Program.","year":"1970","journal-title":"Diabetes"},{"key":"e_1_2_1_91_2","first-page":"255","volume-title":"Effect of tolbutamide (TOLB) treatment on cardiovascular (CV) mortality in the University Group Diabetes Program (UGDP) (abstract)","author":"Williamson JR","year":"1979"},{"key":"e_1_2_1_92_2","first-page":"572","article-title":"Clinical biostatistics XXXVI. The persistent biometric problems of the UGDP study","volume":"19","author":"Feinstein AR.","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_93_2","first-page":"1","article-title":"Long\u2010term tolbutamide treatment after myocardial infarction","volume":"507","author":"Paosikivi J.","year":"1970","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_94_2","first-page":"91","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Lucchesi BR","year":"1975"},{"key":"e_1_2_1_95_2","volume-title":"Diabetes mellitus","author":"Feldman JM."},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90256-5"},{"key":"e_1_2_1_97_2","first-page":"247","article-title":"Effects of the sulphonylurea drug glicazide and glibenclamide on blood glucose control and platelet function","volume":"56","author":"Klaff LJ","year":"1979","journal-title":"S Afr Med J"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)91067-7"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6298.1018"},{"key":"e_1_2_1_100_2","first-page":"216","volume-title":"Micronase: pharmacological and clinical evaluation","author":"Gundersen K","year":"1975"},{"key":"e_1_2_1_101_2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/archinte.1982.00340210094019","article-title":"Lipid metabolism in non\u2010insulin\u2010dependent diabetes mellitus","volume":"142","author":"Greenfeld MS","year":"1982","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_102_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/diab.29.1.41","article-title":"Ten\u2010year follow\u2010up of subjects with impaired glucose tolerance prevention of diabetes by tolbutamide and diet regulation","volume":"29","author":"Sartor G","year":"1980","journal-title":"Diabetes"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312223092504"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312223092505"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.16.7.487"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.18.2.84"},{"key":"e_1_2_1_107_2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/archinte.1969.00300130096013","article-title":"Appraisal of the extrapancreatic actions of sulfonylureas","volume":"123","author":"Feldman JM","year":"1969","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_108_2","first-page":"34","article-title":"Comparative studies on the dynamics of insulin secretion following HB419 and tolbutamide of the perfused rat pancreas and the perifused isolated pieces and islets of rat pancreas","volume":"1","author":"Fussganger RD","year":"1969","journal-title":"Horm Metab Res"},{"key":"e_1_2_1_109_2","first-page":"73","article-title":"Use of glibenclamide in maturity\u2010onset diabetes \u2014 effect of the drug on serum insulin levels","volume":"1","author":"Chandalia HB","year":"1969","journal-title":"Horm Metab Res"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.20.11.745"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(76)90537-4"},{"key":"e_1_2_1_112_2","first-page":"451","article-title":"Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide","volume":"90","author":"Beck\u2010Neilsen H","year":"1979","journal-title":"Acta Endocrinol"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-6-1257"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109894"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90656-3"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257344"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.33.4.346"},{"issue":"1","key":"e_1_2_1_118_2","first-page":"72","article-title":"Oral sulfonylurea agents suppress hepatic glucose production in noninsulin\u2010dependent diabetic individuals","volume":"7","author":"DeFronzo RA","year":"1984","journal-title":"Diabetes Care"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00281304"},{"issue":"1","key":"e_1_2_1_120_2","first-page":"122","article-title":"Glyburide activation of adipocyte glycogen synthetase and potentiation of insulin action","author":"Swartz FW","year":"1984","journal-title":"Diabetes"},{"key":"e_1_2_1_121_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2337\/diab.33.5.495","article-title":"Tolbutamide stimulates fructose\u20102,6\u2010bisphosphate formation in perfused rat liver","volume":"33","author":"Matsutani A","year":"1984","journal-title":"Diabetes"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110112"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(72)90180-3"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90164-0"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00745132"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1980.tb06527.x"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00507101"},{"issue":"1","key":"e_1_2_1_128_2","first-page":"25","article-title":"Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man","volume":"7","author":"Pfeifer MA","year":"1984","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_2_1_129_2","first-page":"17","article-title":"Insulin secretion and insulin action in non\u2010insulin dependent\u2010diabetes mellitus: which defect is primary?","volume":"7","author":"Reaven GM.","year":"1984","journal-title":"Diabetes Care"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01228302"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90248-6"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90253-X"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606420"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1070169"},{"key":"e_1_2_1_135_2","first-page":"97","article-title":"The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes","volume":"106","author":"Groop L","year":"1984","journal-title":"Acta Endocrinol"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90179-7"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.30.9.739"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.31.10.890"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.6.1.75"},{"key":"e_1_2_1_140_2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/jama.1970.03180100027005","article-title":"Factors associated with long\u2010term survival of diabetics","volume":"214","author":"Pell S","year":"1970","journal-title":"JAMA"},{"key":"e_1_2_1_141_2","first-page":"27","article-title":"1983 national prescription audit: Top 200 drug products account for 1.8% of all prescriptions","year":"1984","journal-title":"Pharmacy Times"},{"key":"e_1_2_1_142_2","first-page":"113","article-title":"Utilization of antidiabetic drugs in the nordic countries","volume":"262","author":"Andrew M.","year":"1984","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_143_2","volume-title":"DiaBeta package insert","author":"Hoechst\u2010Roussel Pharmaceuticals Inc.","year":"1984"},{"key":"e_1_2_1_144_2","volume-title":"Micronase package insert","author":"The Upjohn Co.","year":"1984"},{"key":"e_1_2_1_145_2","volume-title":"Glucotrol package insert","author":"Pfizer Inc.","year":"1984"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1985.tb03404.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1985.tb03404.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1985.tb03404.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:06:00Z","timestamp":1761044760000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1985.tb03404.x"}},"subtitle":["History, Chemistry, Metabolism, Pharmacokinetics, Clinical Use and Adverse Effects"],"short-title":[],"issued":{"date-parts":[[1985,3,4]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,3,4]]}},"alternative-id":["10.1002\/j.1875-9114.1985.tb03404.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1985.tb03404.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,3,4]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}